Expert Outlines Collaborative Integrative Oncology Plans in Kidney Cancer

Article

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.

Santosh Rao, MD, spoke with CancerNetwork® during Kidney Cancer Awareness Month 2023 about plans to expand University Hospitals Connor Whole Health, the integrative oncology wing of University Hospitals that will help to provide several types of clinical services to patients with cancer, including kidney cancer. This includes everything from acupuncture and massage to art therapy and meditation.

Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, emphasized the collaborative nature of providing integrative care for patients at his institution. In terms of strategy, he noted a “synergy” among the different experts in supportive oncology, palliative care, and integrative oncology who all work together to improve inpatient and outpatient care, referral patterns, and symptom management for those receiving treatment at Connor Whole Health.

Transcript:

We’re building our integrative oncology program. Our integrative oncology program is part of University Hospitals, but it’s under a program called University Hospitals Connor Whole Health. And this is a whole wing of University Hospital Health that is responsible for integrative medicine as a whole. We work very closely with supportive oncology and palliative care, and we have a lot of strategies on how we can work together both on the inpatient and outpatient side.

A lot of these things are plans at this point. As of now, a lot of it is just collaboration between the different programs. But there’s a lot of synergy in many places around the world with palliative care, integrative medicine, and integrative oncology. We plan to pattern ourselves after that, some of which will happen in the hospital, where we really plan to offer complementary therapies alongside supportive oncology to help our patients with pain and other symptoms. And then we’ll try to do some of that on the outpatient side, as well, and to have referrals that make sense for some of the patients who have symptoms.

Reference

Integrative Health Services for Well-Being and Healing. University Hospitals Connor Whole Health. Accessed April 7, 2023. http://bit.ly/3zIRixi

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Related Content